Hilde Jalving

Hilde Jalving is a researcher in the Department of Onco-Immunology at the University of Groningen’s Faculty of Medical Sciences/UMCG. Her work focuses on oncology and immunology, particularly melanoma, immune checkpoint inhibitors, and cancer treatment outcomes. She has authored over 144 publications and actively participates in academic activities, including presentations and supervising PhD students. In 2017, she received the Young Investigator Grant Dutch for her research in malignant neoplasms and melanoma.

• Education: MD and PhD (details not specified).
• Research Interests: Melanoma treatment protocols, adjuvant therapies, immune checkpoint inhibitors, and translational oncology. She also explores metabolic risk factors in skin cancer and drug hypersensitivity management.

Her recent articles address adjuvant treatments for BRAF-mutated melanoma, immunotherapy strategies for resectable melanoma, and the role of metabolic markers in skin cancer risk. Jalving frequently presents at conferences, discussing topics like Merkel cell carcinoma updates and sustainable oncology practices.

• Awards: Young Investigator Grant Dutch (2017).
• Media Engagement: Featured in podcasts like ‘Medische Oncologie’ discussing the NADINA study and environmental impacts of medication.